Compugen Ltd (CGEN) 9.04 $CGEN
Global Bone Marrow Transplantation Therapeutics Pipeline Review 2014 - 7 Companies & 10 Drug Profiles
M2 - Fri Sep 12, 3:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fxqmms/bone_marrow) has announced the addition of the "Bone Marrow Transplantation - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Bone Marrow Transplantation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bone Marrow Transplantation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Mesoblast Limited - Cleveland BioLabs, Inc. - Compugen Ltd. - Pluristem Therapeutics Inc. - Spectrum Pharmaceuticals, Inc. - TikoMed AB - Taiga Biotechnologies, Inc. Drug Profiles - melphalan - Allogeneic MPC for Bone Marrow Transplantation - TM-400 - PLX-BMP - CBLB-612 - CBLB-612 - CGEN-15001 - Small Molecule to Inhibit Perforin for Bone Marrow Transplantation - Central Memory T Cell Therapy for Bone Marrow Transplantation - Protein for Bone Marrow Transplantation For more information visit http://www.researchandmarkets.com/research/fx...one_marrow
Can The Uptrend Continue for Compugen (CGEN)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 8:32AM CDT
Can The Uptrend Continue for Compugen (CGEN)?
Compugen Honoured as a Winner of Microsoft's Excellence in Operations -- Gold Level Award
Marketwire Canada - Thu Sep 04, 11:00AM CDT
Today Compugen announced it has won the Gold Level Excellence in Operations Award for delivering market-leading operational excellence supporting Microsoft technology over the past year.
Compugen (CGEN): Strong Industry, Solid Earnings Estimate Revisions - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 7:39AM CDT
Compugen is seeing solid earnings estimate revision activity and also has a great company from a Zacks Industry Rank perspective
Drug Discovery Technologies - A Global Market Overview
M2 - Fri Aug 29, 5:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dtdx3f/drug_discovery) has announced the addition of the "Drug Discovery Technologies - A Global Market Overview" report to their offering. The development of new drugs for treating difficult diseases, such as cancer requires extensive expenditure, in addition to consuming a lot of time. The first step in designing a new drug involves the utilizing high-throughput screening of large chemical libraries for identifying compounds that can provide the requisite therapeutic effect. The capability of visualizing biological activity at the cellular level has constituted a strategic component in drug discovery, and adding automation and high-volume screening methods has enabled in testing compounds in large numbers. The field of pharmaceutical research is being provided considerable impetus through the combination of imaging and screening. Key Topics Covered: PART A: GLOBAL MARKET PERSPECTIVE 1. INTRODUCTION 2. KEY MARKET TRENDS 3. RECENT PATENTS IN DRUG DISCOVERY LANDSCAPE 4. KEY GLOBAL PLAYERS 5. KEY BUSINESS TRENDS 6. GLOBAL MARKET OVERVIEW PART B: REGIONAL MARKET PERSPECTIVE 1. THE UNITED STATES 2. EUROPE 3. ASIA-PACIFIC 4. REST OF WORLD PART C: GUIDE TO THE INDUSTRY 1. NORTH AMERICA 2. EUROPE 3. ASIA-PACIFIC 4. REST OF WORLD PART
ANNEXURE 1. RESEARCH METHOLOGY 2. FEEDBACK Companies Mentioned: - 4-Antibody AG - Abbott Laboratories - Accelrys, Inc. - Affymetrix Inc. - Agilent Technologies Inc. - Asahi Kasei Pharma Corporation - Astrazeneca Plc - Aviva Biosciences Corp. - Bayer Healthcare AG - BD Biosciences - Beckman Coulter Inc. - Biacore International AB - Bioanalytical Systems, Inc. - Bio-Rad Laboratories, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Caliper Life Sciences, Inc. - Caprion Proteomics, Inc. - Celera Corporation - Celgene Corporation - Charles River Laboratories International, Inc. - Compugen Ltd. - Decode Genetics, Inc. - EMD Millipore Corporation - Evotec AG - GE Healthcare Ltd. - Genedata AG - Hitgen Ltd - Hudson Robotics, Inc. - Illumina Inc. - Incyte Corporation - Isis Pharmaceuticals, Inc. - Kyowa Hakko Kirin Co., Ltd. - Luminex Corporation - Maxcyte, Inc - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - Molecular Devices, LLC - Molecular Discovery Ltd. - Molecular Discovery Systems Pty., Ltd. - New England Biolabs, Inc. - Novartis AG - Osiris Therapeutics Inc. - Perkinelmer, Inc. - Promega Corporation - Qiagen N.V. - Quantum Pharmaceuticals - Roche Holding AG - Shimadzu Corporation - Sigma-Aldrich Corporation - Sri Biosciences - Tecan Group Ltd. - The National Center for Drug Screening - Thermo Fisher Scientific Inc. - Viva Biotech Ltd - Waters Corp. For more information visit http://www.researchandmarkets.com/research/dt..._discovery
Compugen Has Returned 14.7% Since SmarTrend Recommendation (CGEN)
Comtex SmarTrend(R) - Thu Aug 28, 4:59PM CDT
SmarTrend identified a Downtrend for Compugen (NASDAQ:CGEN) on March 25th, 2014 at $10.37. In approximately 5 months, Compugen has returned 14.71% as of today's recent price of $8.84.
Compugen elects Ari Krashin as CFO
M2 - Tue Aug 26, 7:23AM CDT
Drug discovery company Compugen (NASDAQ:CGEN) disclosed on Monday the addition of Ari Krashin as its chief financial officer.
Compugen names Ari Krashin as new CFO
M2 - Tue Aug 26, 4:39AM CDT
Compugen Ltd (Nasdaq:CGEN), a drug discovery company, announced on Monday the appointment of Ari Krashin as chief financial officer, effective 9 September 2014.
Compugen Appoints Mr. Ari Krashin as Chief Financial Officer
Business Wire - Mon Aug 25, 6:09AM CDT
Compugen Ltd. (NASDAQ: CGEN), a leading drug discovery company focused on therapeutic proteins and monoclonal antibodies in the fields of immunology and oncology, today announced the appointment of Mr. Ari Krashin as Chief Financial Officer, effective as of September 9, 2014. Mr. Krashin will report to Dr. Anat Cohen Dayag, Compugen's President and Chief Executive Officer, and will have direct responsibility for all financial functions of the company, including investor relations, and in addition will oversee the legal function.
Shares of CGEN Down 16.6% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Thu Aug 21, 11:09AM CDT
SmarTrend identified a Downtrend for Compugen (NASDAQ:CGEN) on March 25th, 2014 at $10.37. In approximately 5 months, Compugen has returned 16.64% as of today's recent price of $8.64.
Compugen Reacquires Baize's Financial Interest in Pipeline Product Candidates
Business Wire - Thu Aug 21, 6:10AM CDT
Compugen Ltd. (NASDAQ: CGEN) announced today the signing of a termination and equity conversion agreement with Baize Investments (Israel) Ltd. ("Baize"
, pursuant to which the Company has reacquired Baize's participation rights for certain Pipeline Program candidates. In addition, a warrant to purchase 500,000 Compugen ordinary shares at $7.50 per share previously issued to Baize has been cancelled.
Zacks Rank #1 Additions for Thursday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Aug 14, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
Compugen Ltd. Reports 2nd Quarter 2014 Financial Results
Business Wire - Wed Aug 06, 6:11AM CDT
Compugen Ltd. (NASDAQ: CGEN) today reported financial results for the second quarter ending June 30, 2014.
CORRECTED DATE FOR Q2 CONFERENCE CALL: Compugen Second Quarter 2014 Conference Call Scheduled for Wednesday, August 6, 2014 at 10:00 AM EDT
Business Wire - Thu Jul 31, 6:37AM CDT
Compugen Ltd. (NASDAQ: CGEN) today announced that the Company will host a conference call at 10:00 AM EDT on Wednesday, August 6, 2014 to review the second quarter 2014 results. The quarterly results will be released on the Company's website (www.cgen.com), prior to the conference call. A previous release stating August 5 as the date for the call was in error.
Compugen Second Quarter 2014 Conference Call Scheduled for Tuesday, August 5, 2014 at 10:00 AM EDT
Business Wire - Tue Jul 29, 6:01AM CDT
Compugen Ltd. (NASDAQ: CGEN) today announced that the Company will host a conference call at 10:00 AM EDT on Tuesday, August 5, 2014 to review the second quarter 2014 results. The quarterly results will be released on the Company's website (www.cgen.com), prior to the conference call.
Compugen to Present Immune Checkpoint Related Research at Two Scientific Conferences
Business Wire - Thu Jul 24, 6:02AM CDT
--Results for CGEN-15001 fusion protein based on checkpoint protein candidate to be presented at International Conference on Immune Tolerance in Amsterdam
Compugen Down 15.6% Since SmarTrend Downtrend Call (CGEN)
Comtex SmarTrend(R) - Wed Jul 23, 11:11AM CDT
SmarTrend identified a Downtrend for Compugen (NASDAQ:CGEN) on March 25th, 2014 at $10.37. In approximately 4 months, Compugen has returned 15.58% as of today's recent price of $8.75.
Global Bone Marrow Transplantation Therapeutics Pipeline Review 2014 - 7 Companies & 10 Drug Profiles
M2 - Fri Sep 12, 3:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fxqmms/bone_marrow) has announced the addition of the "Bone Marrow Transplantation - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Bone Marrow Transplantation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bone Marrow Transplantation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Mesoblast Limited - Cleveland BioLabs, Inc. - Compugen Ltd. - Pluristem Therapeutics Inc. - Spectrum Pharmaceuticals, Inc. - TikoMed AB - Taiga Biotechnologies, Inc. Drug Profiles - melphalan - Allogeneic MPC for Bone Marrow Transplantation - TM-400 - PLX-BMP - CBLB-612 - CBLB-612 - CGEN-15001 - Small Molecule to Inhibit Perforin for Bone Marrow Transplantation - Central Memory T Cell Therapy for Bone Marrow Transplantation - Protein for Bone Marrow Transplantation For more information visit http://www.researchandmarkets.com/research/fx...one_marrow
Can The Uptrend Continue for Compugen (CGEN)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 8:32AM CDT
Can The Uptrend Continue for Compugen (CGEN)?
Compugen Honoured as a Winner of Microsoft's Excellence in Operations -- Gold Level Award
Marketwire Canada - Thu Sep 04, 11:00AM CDT
Today Compugen announced it has won the Gold Level Excellence in Operations Award for delivering market-leading operational excellence supporting Microsoft technology over the past year.
Compugen (CGEN): Strong Industry, Solid Earnings Estimate Revisions - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 7:39AM CDT
Compugen is seeing solid earnings estimate revision activity and also has a great company from a Zacks Industry Rank perspective
Drug Discovery Technologies - A Global Market Overview
M2 - Fri Aug 29, 5:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dtdx3f/drug_discovery) has announced the addition of the "Drug Discovery Technologies - A Global Market Overview" report to their offering. The development of new drugs for treating difficult diseases, such as cancer requires extensive expenditure, in addition to consuming a lot of time. The first step in designing a new drug involves the utilizing high-throughput screening of large chemical libraries for identifying compounds that can provide the requisite therapeutic effect. The capability of visualizing biological activity at the cellular level has constituted a strategic component in drug discovery, and adding automation and high-volume screening methods has enabled in testing compounds in large numbers. The field of pharmaceutical research is being provided considerable impetus through the combination of imaging and screening. Key Topics Covered: PART A: GLOBAL MARKET PERSPECTIVE 1. INTRODUCTION 2. KEY MARKET TRENDS 3. RECENT PATENTS IN DRUG DISCOVERY LANDSCAPE 4. KEY GLOBAL PLAYERS 5. KEY BUSINESS TRENDS 6. GLOBAL MARKET OVERVIEW PART B: REGIONAL MARKET PERSPECTIVE 1. THE UNITED STATES 2. EUROPE 3. ASIA-PACIFIC 4. REST OF WORLD PART C: GUIDE TO THE INDUSTRY 1. NORTH AMERICA 2. EUROPE 3. ASIA-PACIFIC 4. REST OF WORLD PART
ANNEXURE 1. RESEARCH METHOLOGY 2. FEEDBACK Companies Mentioned: - 4-Antibody AG - Abbott Laboratories - Accelrys, Inc. - Affymetrix Inc. - Agilent Technologies Inc. - Asahi Kasei Pharma Corporation - Astrazeneca Plc - Aviva Biosciences Corp. - Bayer Healthcare AG - BD Biosciences - Beckman Coulter Inc. - Biacore International AB - Bioanalytical Systems, Inc. - Bio-Rad Laboratories, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Caliper Life Sciences, Inc. - Caprion Proteomics, Inc. - Celera Corporation - Celgene Corporation - Charles River Laboratories International, Inc. - Compugen Ltd. - Decode Genetics, Inc. - EMD Millipore Corporation - Evotec AG - GE Healthcare Ltd. - Genedata AG - Hitgen Ltd - Hudson Robotics, Inc. - Illumina Inc. - Incyte Corporation - Isis Pharmaceuticals, Inc. - Kyowa Hakko Kirin Co., Ltd. - Luminex Corporation - Maxcyte, Inc - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - Molecular Devices, LLC - Molecular Discovery Ltd. - Molecular Discovery Systems Pty., Ltd. - New England Biolabs, Inc. - Novartis AG - Osiris Therapeutics Inc. - Perkinelmer, Inc. - Promega Corporation - Qiagen N.V. - Quantum Pharmaceuticals - Roche Holding AG - Shimadzu Corporation - Sigma-Aldrich Corporation - Sri Biosciences - Tecan Group Ltd. - The National Center for Drug Screening - Thermo Fisher Scientific Inc. - Viva Biotech Ltd - Waters Corp. For more information visit http://www.researchandmarkets.com/research/dt..._discovery Compugen Has Returned 14.7% Since SmarTrend Recommendation (CGEN)
Comtex SmarTrend(R) - Thu Aug 28, 4:59PM CDT
SmarTrend identified a Downtrend for Compugen (NASDAQ:CGEN) on March 25th, 2014 at $10.37. In approximately 5 months, Compugen has returned 14.71% as of today's recent price of $8.84.
Compugen elects Ari Krashin as CFO
M2 - Tue Aug 26, 7:23AM CDT
Drug discovery company Compugen (NASDAQ:CGEN) disclosed on Monday the addition of Ari Krashin as its chief financial officer.
Compugen names Ari Krashin as new CFO
M2 - Tue Aug 26, 4:39AM CDT
Compugen Ltd (Nasdaq:CGEN), a drug discovery company, announced on Monday the appointment of Ari Krashin as chief financial officer, effective 9 September 2014.
Compugen Appoints Mr. Ari Krashin as Chief Financial Officer
Business Wire - Mon Aug 25, 6:09AM CDT
Compugen Ltd. (NASDAQ: CGEN), a leading drug discovery company focused on therapeutic proteins and monoclonal antibodies in the fields of immunology and oncology, today announced the appointment of Mr. Ari Krashin as Chief Financial Officer, effective as of September 9, 2014. Mr. Krashin will report to Dr. Anat Cohen Dayag, Compugen's President and Chief Executive Officer, and will have direct responsibility for all financial functions of the company, including investor relations, and in addition will oversee the legal function.
Shares of CGEN Down 16.6% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Thu Aug 21, 11:09AM CDT
SmarTrend identified a Downtrend for Compugen (NASDAQ:CGEN) on March 25th, 2014 at $10.37. In approximately 5 months, Compugen has returned 16.64% as of today's recent price of $8.64.
Compugen Reacquires Baize's Financial Interest in Pipeline Product Candidates
Business Wire - Thu Aug 21, 6:10AM CDT
Compugen Ltd. (NASDAQ: CGEN) announced today the signing of a termination and equity conversion agreement with Baize Investments (Israel) Ltd. ("Baize"
, pursuant to which the Company has reacquired Baize's participation rights for certain Pipeline Program candidates. In addition, a warrant to purchase 500,000 Compugen ordinary shares at $7.50 per share previously issued to Baize has been cancelled. Zacks Rank #1 Additions for Thursday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Aug 14, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
Compugen Ltd. Reports 2nd Quarter 2014 Financial Results
Business Wire - Wed Aug 06, 6:11AM CDT
Compugen Ltd. (NASDAQ: CGEN) today reported financial results for the second quarter ending June 30, 2014.
CORRECTED DATE FOR Q2 CONFERENCE CALL: Compugen Second Quarter 2014 Conference Call Scheduled for Wednesday, August 6, 2014 at 10:00 AM EDT
Business Wire - Thu Jul 31, 6:37AM CDT
Compugen Ltd. (NASDAQ: CGEN) today announced that the Company will host a conference call at 10:00 AM EDT on Wednesday, August 6, 2014 to review the second quarter 2014 results. The quarterly results will be released on the Company's website (www.cgen.com), prior to the conference call. A previous release stating August 5 as the date for the call was in error.
Compugen Second Quarter 2014 Conference Call Scheduled for Tuesday, August 5, 2014 at 10:00 AM EDT
Business Wire - Tue Jul 29, 6:01AM CDT
Compugen Ltd. (NASDAQ: CGEN) today announced that the Company will host a conference call at 10:00 AM EDT on Tuesday, August 5, 2014 to review the second quarter 2014 results. The quarterly results will be released on the Company's website (www.cgen.com), prior to the conference call.
Compugen to Present Immune Checkpoint Related Research at Two Scientific Conferences
Business Wire - Thu Jul 24, 6:02AM CDT
--Results for CGEN-15001 fusion protein based on checkpoint protein candidate to be presented at International Conference on Immune Tolerance in Amsterdam
Compugen Down 15.6% Since SmarTrend Downtrend Call (CGEN)
Comtex SmarTrend(R) - Wed Jul 23, 11:11AM CDT
SmarTrend identified a Downtrend for Compugen (NASDAQ:CGEN) on March 25th, 2014 at $10.37. In approximately 4 months, Compugen has returned 15.58% as of today's recent price of $8.75.
